Navigation Links
Hospira Reports First-Quarter 2013 Results
Date:5/1/2013

>$46.7

(354.0)%

$101.2

$104.2

(2.9)%Diluted (Loss) Earnings per Share

$(0.46)

$0.24

(291.7)%

$0.52

$0.47

10.6%Statistics (as a % of Net Sales)Gross Profit (Net Sales less

Cost of Products Sold)

17.0%

31.1%36.4%

37.0%(Loss) Income from

Operations

(13.4)%

4.8%10.2%

10.8%Results under GAAP include items as detailed in the schedules attached to this press release.

Adjusted* net sales (excluding the impact of customer sales allowances associated with the company's device strategy) were $988 million in the first quarter of 2013, an increase of 2.3 percent compared to the first quarter of 2012. Continued strong U.S. sales of Precedex™ and higher pricing on certain Specialty Injectable Pharmaceuticals (SIP) products in the U.S. drove the majority of the increase. These factors more than offset pricing erosion of certain newer U.S. SIP products and lower device sales as a result of an expanded import alert by the U.S. Food and Drug Administration, announced on February 14, 2013. On a GAAP basis, net sales in the quarter were $884 million and include the impact of charges associated with the company's device strategy, announced May 1, 2013.

Adjusted* income from operations decreased 2.9 percent to $101 million in the first quarter of 2013, compared to $104 million in the first quarter of 2012. The decline primarily reflects the impact of costs associated with higher year-over-year manufacturing costs related to quality initiatives and higher research and development (R&D) spending. On a GAAP basis, loss from operations was $119 million compared to income from operations of $47 million in the first quarter of 2012. The decrease was mainly due to the impact of charges related to the company's new device strategy.

The effective tax rate on an adjusted basis* in the quarter was 1.0 percent co
'/>"/>

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. Hospira Reports First-Quarter 2012 Results
3. Hospira to Present at Upcoming Investor Conferences
4. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
5. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
6. Hospira to Host Conference Call for Second-quarter 2012 Results
7. Hospira Expands Board of Directors With Election of Dennis M. Fenton
8. Hospira Reports Second-Quarter 2012 Results
9. Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
10. Hospira Reports Third-Quarter 2012 Results
11. Hospira to Present at the J.P. Morgan 31st Annual Healthcare Conference Jan. 8, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 02, 2015 Research and ... the "Specialty Enzymes - Global Strategic Business Report" ... is also analyzed by the following End-Use Applications: Pharmaceutical ... separate comprehensive analytics for the US, Canada ... Europe , Asia-Pacific , ...
(Date:6/2/2015)... 2015 Today the Council of State ... food companies, retailers, and human and animal health ... Stewardship. CSTE is committed to supporting changes that ... strains, preserve the efficacy of our existing antibiotics, ... CSTE continues to serve as a key ...
(Date:6/2/2015)... June 2, 2015 ANI Pharmaceuticals, Inc. ("ANI") ... received approval from the U.S. Food and Drug Administration ... Oxycodone Hydrochloride Oral Solution 5mg/5mL. Trailing twelve-month sales for ... three current competitors. ANI expects to begin shipping to ... , President and CEO of ANI Pharmaceuticals, stated, "This ...
Breaking Medicine Technology:Specialty Enzymes - Global Strategic Business Report 2015: Indispensable to the Pharmaceutical Industry 2ANI Pharmaceuticals Announces FDA Approval of Oxycodone Hydrochloride Oral Solution 5mg/5mL 2ANI Pharmaceuticals Announces FDA Approval of Oxycodone Hydrochloride Oral Solution 5mg/5mL 3
... DALLAS, March 10 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... conference call for March 13, 2008 at 10:00 a.m. ... its clinical trial programs as,well as its business opportunities., ... dialing (877),407-8293; callers outside the U.S. may participate by ...
... Reported at AAOS Annual Meeting Support Longterm ... ... GENZ ), today announced findings from a large, multicenter,observational study that ... had pain and,functional impairment from defects in the articular cartilage of ...
Cached Medicine Technology:Access Pharmaceuticals to Conduct Conference Call to Update Financial Community 2Genzyme Announces Presentation of New Positive Data on Carticel(R) 2Genzyme Announces Presentation of New Positive Data on Carticel(R) 3Genzyme Announces Presentation of New Positive Data on Carticel(R) 4Genzyme Announces Presentation of New Positive Data on Carticel(R) 5Genzyme Announces Presentation of New Positive Data on Carticel(R) 6
(Date:6/2/2015)... NC (PRWEB) June 02, 2015 ... training and compliance solutions for the healthcare market, ... The Arc to offer 10 complimentary courses relating ... provide public safety professionals with additional resources to ... Safety professionals are often the first responders to ...
(Date:6/2/2015)... Baltimore, MD (PRWEB) June 02, 2015 ... a Baltimore-based creative marketing, web design and development agency, ... initiative. , National Autism Resources’ new website ... with people of all ages diagnosed with autism. The ... community and offer an array of resources, from easy ...
(Date:6/2/2015)... With the approaching summer shaping up as ... United States, people will spend an increasing amount of ... of air conditioning, a recent CBS News article* warned ... allergic reactions. Fresh water advocate Sharon Kleyne, host of ... will discuss the potential side effects of air conditioning ...
(Date:6/2/2015)... PhishLine, LLC today announced it will ... Suite 125 in Waukesha, Wisconsin 53186. The ... of operations for PhishLine’s current corporate staff and ... Mark Chapman, Founder and President, commented “PhishLine is ... customers adopt our market leading service to address ...
(Date:6/2/2015)... Residents of Monarch Landing in Naperville are ... fitness class, do yoga, play volleyball, or participate in ... the Alzheimer’s Association’s Walk to End Alzheimer’s on September ... in a challenge to exercise for 60 days, sponsored ... , While the walk will raise awareness of Alzheimer’s ...
Breaking Medicine News(10 mins):Health News:Relias Learning Partners with Behavioral Health and Developmental Disabilities Leaders to Offer Complimentary Resources to Public Safety Professionals 2Health News:Relias Learning Partners with Behavioral Health and Developmental Disabilities Leaders to Offer Complimentary Resources to Public Safety Professionals 3Health News:National Autism Resources Launches New Website, Delivering More Products and Services 2Health News:National Autism Resources Launches New Website, Delivering More Products and Services 3Health News:Air conditioning may contribute to dry eye, dehydration and allergies warns fresh water advocate Sharon Kleyne 2Health News:Air conditioning may contribute to dry eye, dehydration and allergies warns fresh water advocate Sharon Kleyne 3Health News:PhishLine, LLC Announces New Corporate Headquarters 2Health News:Monarch Landing Takes 60-Day Exercise Challenge to Combat Alzheimer’s 2Health News:Monarch Landing Takes 60-Day Exercise Challenge to Combat Alzheimer’s 3
... Associates will host a community health fair in the Shoh-Sohail ... will include free health screenings for the local community, will ... VHA Building on the Mandalay Canal, 220 Las Colinas Blvd, ... will be hosted in an effort to inform, educate and ...
... the availability of Trade Alerts on stocks making news today. ... free by visiting: http://www.BeaconEquity.com/m Today,s Trade Alerts include: ... (NYSE: ABT ), Eli Lilly & Co. (NYSE: ... ), Novartis AG (NYSE: NVS ) and GlaxoSmithKline ...
... Feb. 18 SpectraScience, Inc. (OTC Bulletin Board: ... it will place its LUMA(R) Cervical Imaging System ... located in Edina, Minnesota.Dr. James B. Presthus, co-founder ... of the LUMA System represents our continued dedication ...
... affairs departments in deploying comprehensive investigator-initiated research grant management program ... ... 18, 2009 -- Clinipace, a growing clinical research solutions company, ... firms to deploy its TEMPO™ for Grant Management ...
... is warranted, experts say , , WEDNESDAY, Feb. 18 (HealthDay News) ... human fetal stem cell therapy has been reported in Moscow, ... to the growths. , The tumors appeared along ... after he began receiving the neural fetal stem cell treatment ...
... Feb. 18 Inverness Medical Innovations, Inc. (NYSE: ... charge of their health at home through the merger of ... for the quarter ended December 31, 2008.In the fourth quarter ... compared to net revenue of $288.0 million in the fourth ...
Cached Medicine News:Health News:Las Colinas FREE Community Health Fair Benefiting the Shoh-Sohail Family of Irving 2Health News:Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: JNJ, ABT, LLY, PFE, NVS, GSK 2Health News:LUMA Cervical Imaging System Installed in Edina at Minnesota Gynecology 2Health News:LUMA Cervical Imaging System Installed in Edina at Minnesota Gynecology 3Health News:Two Pharmaceutical Firms Select Clinipace to Deploy New Grant Management Solution 2Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 2Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 3Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 4Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 5Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 6Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 7Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 8Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 9Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 10Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 11Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 12Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 13Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 14Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 15Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 16Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 17Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 18
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: